We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

UGPA3:BMFBOVESPAUltrapar Participacoes S.A. Analysis

Data as of 2026-06-11 - not real-time

R$24.98

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Ultrapar trades at R$24.98, well below its DCF fair value of R$41.37, implying an upside of nearly 29%. The stock’s P/E of 8.8x is dramatically lower than the industry average of 21.3x, and it offers a generous 7% dividend yield with a payout ratio under 50%, suggesting room for sustainable payouts. Revenue growth of roughly 10% and solid cash generation (operating cash flow > R$6.5bn) reinforce the valuation case, while the price‑to‑book of 1.7x remains modest. Technically, the RSI sits near 31, hinting at oversold conditions, but the MACD remains bearish and volume is on a downtrend, placing the price near a key support level of R$24.21. The beta of 0.31 signals low market sensitivity, yet 30‑day volatility exceeds 28%, indicating short‑term price swings. Overall, the combination of deep valuation discounts, strong dividend appeal, and resilient cash flow supports a buying thesis, while the technical weakness suggests patience until the price confirms a bounce above the R$29.86 resistance.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Significant valuation gap to DCF fair value
  • High dividend yield with sustainable payout
  • Oversold RSI indicating potential near‑term bounce

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Projected price movement toward R$29.86 resistance
  • Consistent revenue growth and cash flow generation
  • Low beta reducing market‑wide downside exposure

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Diversified energy, logistics, and mobility businesses
  • Sustainable dividend policy supported by strong free cash flow
  • Undervalued multiples relative to industry peers

Key Metrics & Analysis

Financial Health

Revenue Growth10.30%
Profit Margin2.06%
P/E Ratio8.8
ROE19.18%
ROA8.30%
Debt/Equity114.11
P/B Ratio1.7
Op. Cash FlowR$6.6B
Free Cash FlowR$2.9B
Industry P/E21.3

Technical Analysis

TrendNeutral
RSI30.8
SupportR$24.21
ResistanceR$29.86
MA 20R$27.04
MA 50R$28.58
MA 200R$24.21
MACDBearish
VolumeDecreasing
Fear & Greed Index86.71

Valuation

Fair ValueR$41.37
Target PriceR$32.18
Upside/Downside28.80%
GradeUndervalued
TypeValue
Dividend Yield7.00%

Risk Assessment

Beta0.46
Volatility28.31%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.